Moreover, endothelial-protective and renoprotective agents—such as SGLT2 inhibitors, renin–angiotensin system blockers, and nitric oxide–enhancing compounds—have been shown to improve vascular integrity in CKD populations, and such vascular benefits may extend to retinal microcirculation (30). This evidence concerns the gene SLC5A2 and chronic kidney disease.